Spontaneous Bacterial Peritonitis Clinical Trial
Official title:
Meropenem vs Cefotaxime as Empirical Treatment of Spontaneous Bacterial Peritonitis :Prospective Randomized Clinical Trial
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.
Ascites is the most frequent complication of cirrhosis and represents a significant change for the patient because the impact on mortality and quality of life is important. Spontaneous bacterial peritonitis (SBP) is a dreaded complication in patients with decompensated cirrhosis. Spontaneous bacterial peritonitis (SBP) is the most frequent and life-threatening infection in patients with liver cirrhosis requiring prompt recognition and treatment. It is defined by the presence of >250 polymorphonuclear cells (PMN)/mm3 in ascites in the absence of an intra-abdominal source of infection or malignancy. Spontaneous bacterial peritonitis carries a mortality rate of 30 to 70% in patients with end-stage liver and kidney disease. Choice of antibiotic is dependent on type of microbes responsible for infection. Gram negative enteric bacteria are considered the most common pathogens responsible for SBP. This is the reason, 3rd generation cephalosporins are the recommended drugs of choice for treating SBP empirically. But recent studies have shown that Cephalosporins are effective only in 70% of community acquired and 56% of hospital acquired SBP.It is most likely due to changing bacterial pathogens of SBP over last two decades as now gram positive bacteria and multi drug resistance organism (MDRO) are increasingly being isolated in SBP. It is the consequence of undue, over the counter misuse of cephalosporins in community and frequent exposure of cirrhosis patients to these drugs during recurrent hospital admissions. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
| Withdrawn |
NCT02552862 -
Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)
|
Phase 3 | |
| Completed |
NCT01193426 -
Diagnostic of Spontaneous Bacterial Peritonitis
|
||
| Completed |
NCT02528097 -
A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis
|
N/A | |
| Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
| Active, not recruiting |
NCT04159870 -
Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
|
Phase 3 | |
| Completed |
NCT04153604 -
Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis
|
||
| Completed |
NCT06234046 -
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
|
Phase 3 | |
| Recruiting |
NCT01598870 -
Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
| Recruiting |
NCT00761098 -
Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
|
Phase 4 | |
| Completed |
NCT05401721 -
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
|
||
| Completed |
NCT02468089 -
To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis
|
N/A | |
| Not yet recruiting |
NCT04746937 -
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
|
Phase 3 | |
| Recruiting |
NCT02759497 -
Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
| Completed |
NCT02608658 -
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
|
N/A | |
| Completed |
NCT02388035 -
Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
|
N/A | |
| Completed |
NCT03163745 -
Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis
|
||
| Completed |
NCT04273373 -
Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.
|
N/A | |
| Active, not recruiting |
NCT04395365 -
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis
|
Phase 3 | |
| Terminated |
NCT00570960 -
Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis
|
Phase 4 |